Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 232
Filtrar
1.
Anesth Analg ; 132(4): 979-992, 2021 04 01.
Artigo em Inglês | MEDLINE | ID: mdl-32665470

RESUMO

BACKGROUND: Drugs such as propofol and ketamine are used alone or in combination to provide sedation for medical procedures in children. The purpose of this systematic review was to compare the safety and effectiveness of propofol and ketamine to other drug regimens. METHODS: We searched Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Web of Science, and the grey literature (meta-Register of Controlled Trials, ClinicalTrials.gov, and Google Scholar) for randomized controlled studies comparing intravenous propofol and ketamine to any other single or combination drug regimen administered to children undergoing diagnostic or therapeutic procedures. Meta-analyses were performed for primary (hemodynamic and respiratory adverse events) and secondary outcomes using RevMan 5.3. We assessed the risk of bias and the certainty (quality) evidence for all outcomes using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. RESULTS: Twenty-nine studies were included for analysis. Based on low-to-moderate quality evidence, we concluded that the use of propofol and ketamine may result in a slight-to-small reduction in the risk of hypotension, bradycardia, and apnea, and a slight increase in the risk of tachycardia, hypertension, and other respiratory adverse events, such as cough or laryngospasm. The ratio of propofol to ketamine and comparator drug regimen subgroups effects were important for desaturation and some secondary outcomes. CONCLUSIONS: The use of propofol and ketamine had a minimal effect on the incidence of adverse events and other secondary outcomes. Large-scale studies are required to more accurately estimate adverse event rates and the effects of propofol and ketamine on patient-important outcomes.


Assuntos
Anestésicos Combinados/uso terapêutico , Anestésicos Dissociativos/uso terapêutico , Anestésicos Intravenosos/uso terapêutico , Sedação Consciente , Estado de Consciência/efeitos dos fármacos , Sedação Profunda , Hipnóticos e Sedativos/uso terapêutico , Ketamina/uso terapêutico , Propofol/uso terapêutico , Adolescente , Fatores Etários , Anestésicos Combinados/efeitos adversos , Anestésicos Dissociativos/efeitos adversos , Anestésicos Intravenosos/efeitos adversos , Criança , Pré-Escolar , Sedação Consciente/efeitos adversos , Sedação Profunda/efeitos adversos , Feminino , Humanos , Hipnóticos e Sedativos/efeitos adversos , Lactente , Recém-Nascido , Ketamina/efeitos adversos , Masculino , Propofol/efeitos adversos , Medição de Risco , Fatores de Risco , Resultado do Tratamento
3.
Med Sci Monit ; 26: e921063, 2020 May 13.
Artigo em Inglês | MEDLINE | ID: mdl-32400392

RESUMO

BACKGROUND The efficacy of a eutectic mixture of local anesthetics (EMLA) for pain control in extracorporeal shock wave lithotripsy is unclear. The aim of this study was to assess the effect of EMLA cream on pain control during extracorporeal shock wave lithotripsy. MATERIAL AND METHODS We searched Medline, EMBASE, and the Cochrane Central Register of Controlled Trials to identify relevant randomized controlled trials that compared the pain control efficacies of EMLA vs. placebo. Study eligibility criteria, participants, and interventions: Randomized controlled trials that compared the effect of EMLA with placebo cream for patients underwent extracorporeal shock wave lithotripsy. Study appraisal and synthesis methods: Two review authors extracted data independently using a designed data extraction form and risk of bias by Cochrane Collaboration's tool. RESULTS Nine studies, including 10 randomized controlled trials with 1167 patients, were eligible. The EMLA group experienced less pain (mean difference, -0.47; 95% confidence interval, -0.78 to -0.16; p=0.003) and shorter duration of lithotripsy (mean difference, -1.70, 95% confidence interval: -2.31 to -1.10, p<0.0001) than the placebo group. There were no significant differences in the number of patients who needed extra intravenous medication (p=0.610), number of patients with insufficient extracorporeal shock wave lithotripsy pain control (p=0.530), and number of patients with opioid adverse effects (p=0.320). Limitations: Long interval between the studies, different kinds of lithotripters. CONCLUSIONS EMLA can reduce pain during the ESWL procedure.


Assuntos
Anestésicos Locais/uso terapêutico , Litotripsia/efeitos adversos , Manejo da Dor/métodos , Analgesia/métodos , Analgésicos Opioides/uso terapêutico , Anestesia Local/métodos , Anestésicos Combinados/uso terapêutico , Humanos , Lidocaína/uso terapêutico , Combinação Lidocaína e Prilocaína/uso terapêutico , Litotripsia/métodos , Dor/etiologia , Medição da Dor
4.
Medicine (Baltimore) ; 98(20): e15712, 2019 May.
Artigo em Inglês | MEDLINE | ID: mdl-31096522

RESUMO

BACKGROUND: Sedation with etomidate or propofol alone during gastroscopy has many side effects. A systematic review and meta-analysis were conducted to evaluate the safety and efficacy of the combined use of propofol and etomidate for sedation during gastroscopy. METHODS: PubMed, Embase, Medline (via Ovid SP), Cochrane library databases, CINAHL (via EBSCO), China Biology Medicine disc (CBMdisc), Wanfang, VIP, and China National Knowledge Infrastructure (CNKI) databases were systematically searched. We included randomized controlled trials (RCTs) comparing the combined use of propofol and etomidate vs etomidate or propofol alone for sedation during gastroscopy. Data were pooled using the random-effects models or fixed-effect model based on heterogeneity. RESULTS: Fifteen studies with 2973 participants were included in the analysis. Compared to propofol alone, the combined use of propofol and etomidate possibly increased recovery time (SMD = 0.14, 95% CI = 0.04-0.24; P = .005), and the risk for myoclonus (OR = 3.07, 95% CI = 1.73-5.44; P < .001), injection pain, and nausea and vomiting. Furthermore, compared to propofol alone, the combination of propofol and etomidate produced an apparent beneficial effect for mean arterial pressure (MAP) after anesthesia (SMD = 1.32, 95% CI = 0.38-2.26; P = .006), SPO2 after anesthesia (SMD = 0.99, 95% CI = 0.43-1.55; P < .001), apnea or hypoxemia (OR = 0.16, 95% CI = 0.08-0.33; P < .001), injection pain, and body movement. Further, compared to etomidate alone, the combination of propofol and etomidate reduced the risk for myoclonus (OR = 0.15, 95% CI = 0.11-0.22; P < .001), body movement, and nausea and vomiting. CONCLUSION: The combination of propofol and etomidate might increase recovery time vs that associated with propofol, but it had fewer side effects on circulation and respiration in patients undergoing gastroscopy. The combined use of propofol and etomidate can improve and produce an apparent beneficial effect on the adverse effects of propofol or etomidate alone, and it was safer and more effective than propofol or etomidate alone.


Assuntos
Anestésicos Combinados/efeitos adversos , Etomidato/efeitos adversos , Gastroscopia/métodos , Propofol/efeitos adversos , Anestésicos Combinados/administração & dosagem , Anestésicos Combinados/uso terapêutico , Anestésicos Intravenosos/efeitos adversos , Anestésicos Intravenosos/uso terapêutico , Pressão Arterial/efeitos dos fármacos , China/epidemiologia , Etomidato/administração & dosagem , Etomidato/uso terapêutico , Feminino , Humanos , Hipóxia/induzido quimicamente , Reação no Local da Injeção/patologia , Masculino , Mioclonia/induzido quimicamente , Náusea/induzido quimicamente , Propofol/administração & dosagem , Propofol/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Risco , Vômito/induzido quimicamente
5.
Arch Razi Inst ; 74(1): 69-75, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-31013008

RESUMO

Anesthesia and analgesia are important in human and veterinary medicine, especially in surgical procedures. Rodents, avians, and exotic species are required to be anesthetized using an appropriate anesthetic regimen. This study aimed to suggest a new anesthetic drug and method in order to facilitate anesthesia as well as analgesia among rabbits, laboratory animals, and humans. Spinal injection of dexamethasone combined with intramuscular ketamine among rabbits can play the role of premedication agents. A total of 24 healthy white adult rabbits from New-Zealand were equally assigned into four groups. Groups 1, 2, 3, and 4 were subjected to spinal xylazine (5mg/kg) with ketamine (35mg/kg,IM), spinal dexamethasone (0.37mg/kg-four times diluted) with ketamine (35mg/kg,IM), dexamethasone (4mg/kg,IM) with ketamine (35mg/kg,IM), and spinal dexamethasone (0.37mg/kg-four times diluted), respectively. The results showed that there was a significant difference in terms of clinical reflexes recorded for group 2, compared to groups 1 and 3. A significant difference was also observed regarding clinical reflexes between group 2 and the other groups. Furthermore, no abnormality was observed in terms of histological sections within groups 2 and 4. Spinal dexamethasone can be used as a premedication combined with ketamine in rabbit anesthesia.


Assuntos
Analgésicos/uso terapêutico , Anestésicos Combinados/uso terapêutico , Dexametasona/uso terapêutico , Ketamina/uso terapêutico , Pré-Medicação/veterinária , Animais , Hipnóticos e Sedativos/uso terapêutico , Injeções Espinhais/veterinária , Masculino , Fármacos Neuromusculares/uso terapêutico , Pré-Medicação/métodos , Coelhos , Xilazina/uso terapêutico
6.
Medicine (Baltimore) ; 98(2): e14087, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30633218

RESUMO

BACKGROUD: The purpose of this study was to evaluate the effects of trigger point injection (TPI) and eutectic mixture local anesthetics (EMLA) cream on the postoperative shoulder pain in patients undergoing total laparoscopic hysterectomy. METHODS: In this randomized, single-blinded, and controlled study, total 75 patients were randomly allocated to TPI group (n = 25), EMLA group (n = 25), and control group (n = 25). TPI group received TPIs with 2 mL of 0.2% ropivacaine, and EMLA group received an occlusive dressing with EMLA cream 2 g on both shoulders. Overall, abdominal, and shoulder pains were evaluated at rest and in motion on postoperative day 3. RESULTS: The incidence of shoulder pain was significantly reduced in EMLA group (56%) compared to control (88%) or TPI (88%) groups (P = .025 in both); the severity of shoulder pain was mitigated in EMLA and TPI groups compared to control group (P < .001, each). Consequently, the overall pain decreased in EMLA group and TPI group (P = .023). The patients with exercise habit (n = 31) showed lower incidence of pain than patients without exercise habit (n = 26) (P = .002, P = .005, and P = .037 in overall, abdominal, and shoulder pain, respectively). TPI or EMLA treatments decreased shoulder pain irrespective of exercise habit (P = .001 and P < .001, respectively), but decreased overall pain only in patients without exercise habit (P = .019). Lastly, EMLA lowered overall pain score at the time of first analgesic request in ward compared to control group (P = .02). CONCLUSIONS: TPI and EMLA with occlusive dressing effectively reduced the shoulder pain after total laparoscopic hysterectomy.


Assuntos
Anestésicos Combinados/uso terapêutico , Anestésicos Locais/uso terapêutico , Histerectomia , Combinação Lidocaína e Prilocaína/uso terapêutico , Dor Pós-Operatória/tratamento farmacológico , Ropivacaina/uso terapêutico , Dor de Ombro/tratamento farmacológico , Adulto , Idoso , Feminino , Humanos , Histerectomia/métodos , Injeções , Laparoscopia , Pessoa de Meia-Idade , Curativos Oclusivos , Dor de Ombro/etiologia , Método Simples-Cego , Resultado do Tratamento , Pontos-Gatilho
7.
Lung Cancer ; 127: 19-24, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30642546

RESUMO

OBJECTIVES: ALK tyrosine kinase inhibitors (TKIs), including crizotinib and several next generation TKIs, have demonstrated beneficial clinical outcomes in ALK-positive non-small cell lung cancer (NSCLC). However, resistance mechanisms following multiple TKI treatments in ALK-positive NSCLC are not fully elucidated. MATERIALS AND METHODS: Mutation profiles of 422 cancer-relevant genes in 52 patients with post-TKI biopsy samples were analyzed using next-generation sequencing (NGS), and compared between patients receiving crizotinib alone (n = 35) and multi-TKIs (n = 17). RESULTS: EML4-ALK variant 3 is the most frequent ALK variants in this cohort, followed by EML4-ALK variant 1. Half of the patients harbored ALK activating mutations upon progression on crizotinib treatment. After multi-TKIs treatment, 59% of the cases developed resistant ALK mutations, and concomitant ALK activating mutations were more commonly observed in this cohort (P = 0.031). Specifically, ALK G1269 A, L1196 M, and C1156Y substitutions were more common in crizotinib-alone samples, while ALK G1202R was significantly more enriched post-multi-TKIs (P = 0.009). Activated bypass signaling tended to be more prevalent in patients post-multi-TKIs. Furthermore, dual activation of ALK and bypass signaling was more frequently found in the multi-TKIs group (5/17, 29%) in contrast to crizotinib-alone (2/35, 6%) (P = 0.031). Additionally, concurrent TP53 mutation demonstrated significantly shorter progression-free survival (PFS) compared with TP53 wildtype in crizotinib-alone group (median PFS: 8 vs 13 months, Hazard Ratio = 1.494, P = 0.019). CONCLUSION: Concurrent ALK activating mutations and/or upregulated bypass signaling are more enriched in patients undergoing multiple ALK TKI treatments compared to crizotinib alone. Concomitant TP53 mutation correlated to unfavorable survival when receiving a single TKI crizotinib.


Assuntos
Anestésicos Combinados/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Crizotinibe/uso terapêutico , Neoplasias Pulmonares/tratamento farmacológico , Inibidores de Proteínas Quinases/uso terapêutico , Adulto , Idoso , Quinase do Linfoma Anaplásico/antagonistas & inibidores , Quinase do Linfoma Anaplásico/genética , Quinase do Linfoma Anaplásico/metabolismo , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Estudos de Coortes , Resistencia a Medicamentos Antineoplásicos , Feminino , Humanos , Neoplasias Pulmonares/mortalidade , Masculino , Pessoa de Meia-Idade , Mutação/genética , Análise de Sobrevida , Resultado do Tratamento
8.
Can Vet J ; 60(1): 55-59, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30651651

RESUMO

This study assessed the effects of a combination of dexmedetomidine and butorphanol on the Schirmer tear test I (STT I) values in dogs. Ninety-eight dogs were sedated with an intramuscular injection of a combination of dexmedetomidine, 5 µg/kg body weight (BW), and butorphanol, 0.2 mg/kg BW. The effects of dexmedetomidine were reversed by administering atipamezole at the end of the procedure. The combination of dexmedetomidine and butorphanol significantly decreased tear production 15 minutes after sedation. The STT I values 15 minutes after reversal of dexmedetomidine with atipamezole were significantly higher than the STT I values 15 minutes after sedation but were significantly lower than the STT I values before sedation. Gender, weight, duration of sedation, right or left eye did not affect STT I values after sedation. It is recommended that dogs sedated with a combination of dexmedetomidine and butorphanol be treated with a tear substitute to combat decreased tear production.


Effet de l'association dexmédétomidin-butorphanol intramusculaire sur la production lacrymale chez le chien. L'étude vise à déterminer les effets de l'association dexmédétomidine-butorphanol sur les résultats du test de Schirmer I (STT I) chez le chien. Quatre-vingt-dix-huit chiens ont été sédatés avec l'association dexmédétomidine (5 µg/kg) butorphanol (0,2 mg/kg) intramusculaire. La dexmédétomidine a été antagonisée avec de l'atipamezole en fin de procédure. L'association dexmédétomidine-butorphanol diminue significativement la production lacrimale 15 minutes post-sédation. Les valeurs de STT I 15 minutes post-antagonisation de la dexmédétomidine étaient significativement plus élevées que celles de STT I 15 minutes post-sédation, mais significativement inférieures aux STT I pré-sédation. Les variables genre, poids, durée de la sédation, oeil droit/gauche, n'ont pas significativement influencé les valeurs de STT I post-sédation. L'association dexmédétomidine-butorphanol diminuant significativement leur production lacrimale il est recommandable de traiter les chiens avec des substituts lacrimaux pour éviter la sécheresse oculaire.(Traduit par les auteurs).


Assuntos
Anestésicos Combinados/uso terapêutico , Butorfanol/uso terapêutico , Sedação Consciente/veterinária , Dexmedetomidina/uso terapêutico , Cães/fisiologia , Hipnóticos e Sedativos/uso terapêutico , Lágrimas/fisiologia , Anestésicos Combinados/administração & dosagem , Anestésicos Combinados/farmacologia , Animais , Butorfanol/administração & dosagem , Butorfanol/farmacologia , Dexmedetomidina/administração & dosagem , Dexmedetomidina/farmacologia , Cães/cirurgia , Feminino , Hipnóticos e Sedativos/administração & dosagem , Hipnóticos e Sedativos/farmacologia , Injeções Intramusculares/veterinária , Masculino
9.
Home Healthc Now ; 37(1): 17-22, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30608463

RESUMO

Peripheral venous catheters (PVC) are often used to provide hydration, medications, and blood products when the length of therapy is expected to be less than 1 week. Pain and phlebitis are frequent complications of PVC. Diclofenac and EMLA have been used to minimize these adverse effects; however, conflicting results have been reported regarding which has better outcomes. This double-blind, randomized controlled trial was conducted to compare the efficacy of EMLA and Diclofenac (TDP) in attenuating PVC pain and phlebitis. The inpatient setting was chosen because of the higher frequency of PVC insertions, allowing for a sufficient sample size. One hundred fifty-four subjects were randomly assigned to three groups: EMLA patch (n = 61), a TDP patch (n = 50), or a patch with lubricant gel (n = 46) as a placebo. The pain was measured by Visual Analogue Scale (VAS). Phlebitis was examined based on Boxter criteria in intervals of 6, 12, 18, 24, and 48 hours after PVC insertion. The mean score of VAS was 41.86 ± 22.49 for the control, 39.40 ± 21.60 for TDP, and 38.77 ± 23.28 for the EMLA group, with no significant differences in pain severity between the three groups. The rate of phlebitis in the group with EMLA was significantly higher than the other two groups at 6, 12, and 18 hours (p = 0.02, p = 0.003 and p = 0.04, respectively). In all interval times, the rate of phlebitis in the TDP group was significantly lower than the other groups. Compared with men, women experienced higher rate of phlebitis and intensity of PVC pain. EMLA and TDP had similar analgesic effects, but phlebitis was less frequently observed with TDP, suggesting TDP as a potential medication for reducing pain and phlebitis before PVC insertion.


Assuntos
Anestésicos Combinados/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Cateterismo Periférico/efeitos adversos , Diclofenaco/uso terapêutico , Combinação Lidocaína e Prilocaína/uso terapêutico , Dor/tratamento farmacológico , Adulto , Anestésicos Locais/uso terapêutico , Método Duplo-Cego , Feminino , Humanos , Masculino , Dor/etiologia , Medição da Dor/métodos
10.
Eur J Ophthalmol ; 29(6): 606-614, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-30280604

RESUMO

PURPOSE: To date, no protocol of anesthesia for pediatric ophthalmic surgery is unanimously recognized. The primary anesthetic risks are associated with strabismus surgery, including oculocardiac reflex, postoperative nausea and vomiting, and postoperative pain. METHODS: This was a prospective, monocentric, observational study conducted in a tertiary pediatric ophthalmic unit. Our anesthetic protocol for strabismus surgery included postoperative nausea and vomiting prevention using dexamethasone and ondansetron. No drug-based prevention of oculocardiac reflex or local/locoregional anesthesia was employed. RESULTS: A total of 106 pediatric ophthalmic surgeries completed between November 2015 and May 2016 were analyzed. The mean patient age was 4.4 (range: 0.2-7.3, standard deviation: 2.4) years. Ambulatory rate was 90%. Oculocardiac reflex incidence was 65% during strabismus surgery (34/52), 50% during congenital cataract surgery (4/8), 33% during intramuscular injection of botulinum toxin (1/3), and 0% during other procedures. No asystole occurred. Postoperative nausea and vomiting incidence was 9.6% after strabismus surgery (5/52) and 0% following the other procedures. One child was hospitalized for one night because of persistent postoperative nausea and vomiting. Postoperative pain generally occurred early on in the recovery room and was quickly controlled. Its incidence was higher in patients who underwent strabismus surgery (27%) than in those who underwent other procedures (9%). CONCLUSION: Morbidity associated with ophthalmic pediatric surgery is low and predominantly associated with strabismus surgery. The benefit-risk ratio and cost-effectiveness of oculocardiac reflex prevention should be questioned. Our postoperative nausea and vomiting rate is low, thanks to the use of a well-managed multimodal strategy. Early postoperative pain is usually well-treated but could probably be more effectively prevented.


Assuntos
Anestésicos Combinados/uso terapêutico , Anestésicos Intravenosos/uso terapêutico , Estrabismo/cirurgia , Acetaminofen/administração & dosagem , Anestesia Local/métodos , Anestésicos Combinados/efeitos adversos , Anestésicos Intravenosos/efeitos adversos , Ansiolíticos/uso terapêutico , Catarata/congênito , Criança , Pré-Escolar , Dexametasona/uso terapêutico , Feminino , Glucocorticoides/uso terapêutico , Humanos , Lactente , Masculino , Midazolam/administração & dosagem , Ondansetron/uso terapêutico , Procedimentos Cirúrgicos Oftalmológicos , Dor Pós-Operatória , Náusea e Vômito Pós-Operatórios/tratamento farmacológico , Náusea e Vômito Pós-Operatórios/etiologia , Propofol/administração & dosagem , Estudos Prospectivos , Reflexo Oculocardíaco , Vômito/tratamento farmacológico , Vômito/etiologia
11.
Arq. bras. med. vet. zootec. (Online) ; 69(6): 1521-1528, nov.-dez. 2017. tab
Artigo em Português | LILACS, VETINDEX | ID: biblio-910439

RESUMO

Objetivou-se comparar as alterações cardiorrespiratórias e a analgesia pós-operatória promovidas pela dexmedetomidina e pelo tramadol, quando associados ao midazolam, em felinas. Para tal, foram selecionadas 18 gatas hígidas, divididas em dois grupos randomizados: GDM, tratadas com dexmedetomidina (10µg/kg) e GTM, tratadas com tramadol (2mg/kg), ambos associados a midazolam (0,2mg/kg,) IM. Após 15 minutos, procedeu-se à indução anestésica com propofol (1,46±0,79mL), mantendo-se a anestesia com isoflurano. As felinas foram submetidas à ovário-histerectomia, registrando-se as variáveis cardiorrespiratórias 15 minutos após a MPA (M0), 15 minutos após a indução (M15) e sequencialmente a cada cinco minutos, até o término do procedimento cirúrgico (M20, M25, M30, M35 e M40). A avaliação da dor iniciou-se 30 minutos após o término do procedimento cirúrgico (MP30) e sequencialmente em intervalos de 30 minutos (MP60, MP90, MP120). A partir do MP120, as avaliações foram registradas a cada hora (MP180, MP240 e MP360). A associação dexmedetomidina-midazolam infere diminuição inicial de frequência cardíaca (FC) sem significado clínico e está relacionada à sedação mais pronunciada, à analgesia menor e menos duradoura e a episódios de êmese, quando comparada à associação tramadol-midazolam. Ambos os protocolos denotaram estabilidade cardiorrespiratória e podem ser considerados seguros em felinas submetidas à ovário-histectomia.(AU)


The aim of this study was to compare cardiorespiratory changes and post-operative analgesia provided by dexmedetomidine or tramadol, associated with midazolam, in female cats. For that purpose, 18 healthy cats were assigned to two randomized groups: GDM, which received dexmedetomidine (10 µg/kg) and GTM, which received tramadol (2 mg/kg), both associated with midazolam (0.2 mg/kg) IM. After 15 minutes, anesthesia was induced with propofol (1.46±0.79 mL) and maintained with isofluorane. Ovariohysterectomy was performed and cardiorespiratory variables were registered 15 minutes after pre-anesthetic medication (M0), 15 minutes after anesthetic induction (M15), and every five minutes until the end of the surgical procedure (M20, M25, M30, M35 e M40). Pain evaluation started 30 minutes after the surgery (MP30) and sequentially at thirty-minute intervals (MP60, MP90, MP120). After MP120, each evaluation was registered at every hour (MP180, MP240 e MP360). Dexmedetomidine-midazolam association results in decreases on initial heart rate (HR) without clinical relevance and it is related to pronounced sedation, poor and less durable antinociception and vomiting events, when compared to tramadol-midazolam association. Both protocols indicate cardiorespiratoy stability and safety in cats undergoing ovariohysterectomy.(AU)


Assuntos
Animais , Feminino , Gatos , Dexmedetomidina/análise , Isoflurano/uso terapêutico , Midazolam/análise , Tramadol/análise , Anestésicos Combinados/uso terapêutico , Histerectomia/veterinária , Ovariectomia/veterinária , Taxa Respiratória
12.
PLoS One ; 12(5): e0176589, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28464014

RESUMO

BACKGROUND AND OBJECTIVES: High concentrations of local anesthetics may be neurotoxic for diabetic patients. Additive perineural administration of magnesium was reported to decrease the consumption of local anesthetics for nerve block. It was hypothesized that MgSO4 added to dilute ropivacaine was equianalgesic to more concentrated ropivacaine for toe amputations in diabetic patients. METHODS: Seventy diabetic patients were allocated into 3 groups: 1) perineural 200 mg MgSO4 added to 0.25% ropivacaine, 2) 0.25% ropivacaine alone, and 3) 0.375% ropivacaine alone. All patients underwent popliteal sciatic nerve block that was guided by ultrasonography using the respective regimens. Time of onset, duration of motor and sensory block were recorded. Spontaneous and evoked pain score, worst pain score, additional analgesic consumption, satisfaction score and initial time of analgesic requirement of each patient were documented up to 48 hours postoperatively. RESULTS: In comparison with 0.25% ropivacaine alone, magnesium supplement prolonged the duration of sensory block (p = 0.001), as well as better evoked pain score at 6 hour postoperatively (p = 0.001). In comparison with evoked pain score (1.6/10) in group of 0.375% ropivacaine, magnesium plus 0.25% ropivacaine presented a little higher score (2.5/10) at 6 hour postoperatively (p = 0.001), while lower worst pain score (p = 0.001) and less postoperative total analgesic consumption (p = 0.002). CONCLUSIONS: The regimen of adding 200mg MgSO4 to 0.25% ropivacaine for sciatic nerve block yields equal analgesic effect in comparison with 0.375% ropivacaine. These findings have suggested that supplemental MgSO4 could not improve analgesic quality except reducing the total amount of local anesthetics requirement in diabetic toe amputations with sciatic nerve blocks.


Assuntos
Amputação Cirúrgica , Anestésicos Locais/uso terapêutico , Pé Diabético/cirurgia , Sulfato de Magnésio/uso terapêutico , Bloqueio Nervoso/métodos , Nervo Isquiático/efeitos dos fármacos , Dedos do Pé/cirurgia , Amidas/administração & dosagem , Amidas/uso terapêutico , Amputação Cirúrgica/métodos , Anestésicos Combinados/administração & dosagem , Anestésicos Combinados/uso terapêutico , Anestésicos Locais/administração & dosagem , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Ropivacaina
13.
Prog Orthod ; 18(1): 1, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28066874

RESUMO

BACKGROUND: The initial placement of orthodontic elastomeric separators can be uncomfortable and painful. Therefore, it is important to relieve this disturbing sensation to create a discomfort or pain-free orthodontic visit. The purpose of this study was to investigate the effect of a lidocaine/prilocaine topical anesthetic on pain and discomfort associated with the placement of orthodontic elastomeric separators. METHODS: Fifty subjects aging between 20-35 years were included in this study. In the maxillary arch, a lidocaine/prilocaine topical anesthetic was placed around the ginigval margins of the premolar and molar on side. On the other side, a placebo agent was placed around the ginigval margins of the premolar and molar. After two minutes, an elastomeric separator was placed between the premolar and molar on both sides. The subjects were then asked to report their findings on a Verbal Scale and a Visual Analogue Scale every second minute for a period of 10 min. The subjects were also given a questionnaire to evaluate the overall impression on the topical anesthetic use. RESULTS: The overall mean discomfort/pain score was found to be significantly lower (p < 0.001) with the topical anesthetic than with the placebo. Repeated measures ANOVA with a Greenhouse-Geisser correction determined that mean pain scores were statistically significantly low with the 10-min time duration (F (1.54,42.2) = 40.7, p = 0.001), with an estimated grand mean (8.37, 95% CI 6.75-9.98). The questionnaire responses revealed that 87% of the subjects reported an overall satisfaction and agreement with the topical anesthetic than with the placebo or no difference (13%) after the initial separator placement. CONCLUSIONS: The discomfort and pain resulting from the initial placement of orthodontic elastomeric separators can be significantly reduced with the lidocaine/prilocaine topical anesthetic.


Assuntos
Anestesia Dentária/métodos , Anestésicos Combinados/uso terapêutico , Lidocaína/uso terapêutico , Aparelhos Ortodônticos/efeitos adversos , Prilocaína/uso terapêutico , Adulto , Anestésicos Combinados/administração & dosagem , Anestésicos Locais/administração & dosagem , Anestésicos Locais/uso terapêutico , Feminino , Humanos , Lidocaína/administração & dosagem , Masculino , Medição da Dor , Prilocaína/administração & dosagem , Adulto Jovem
14.
Int Wound J ; 14(4): 606-615, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27500801

RESUMO

Chronic foot and leg ulcers are a common health problem worldwide. A mainstay of chronic ulcer therapy is sharp mechanical wound debridement requiring potent analgesia. In this prospective, controlled, single-centre, crossover design study, patients were assigned to either the administration of topical analgesia with 5% lidocaine/prilocaine cream or the inhalation of an analgesic 50% N2 O/O2 gas premix. Primary outcome parameter was level of pain at maximum wound depth during debridement as measured by a visual analogue scale. Secondary outcomes included level of pain after debridement, overall duration of treatment session, duration and completeness of debridement, and the patient's subjective perception of analgesic quality during debridement. Pain level increased from 0·60/0·94 (first/second debridement; baseline) to 1·76/2·50 (debridement) with 5% lidocaine/prilocaine and from 1·00/1·35 (baseline) to 3·95/3·29 (debridement) with 50% N2 O/O2 gas premix. Patient satisfaction was 90·48%/94·44% (first/second debridement) with topical 5% lidocaine/prilocaine analgesia and 90·48%/76·47% with the inhalation of 50% N2 O/O2 gas premix. Debridement was completed in a significantly higher percentage of 85·71%/88·89% (first/second debridement) with 5% lidocaine/prilocaine than with 50% N2 O/O2 gas premix (42·86%/58·82%) (odds ratio 6·7; P = 0·001). This study provides sound evidence that analgesia with topically administered 5% lidocaine/prilocaine cream is superior to the use of inhaled 50% N2 O/O2 gas premix in chronic leg ulcer debridement.


Assuntos
Anestésicos Locais/uso terapêutico , Desbridamento/métodos , Úlcera da Perna/terapia , Lidocaína/uso terapêutico , Óxido Nitroso/uso terapêutico , Dor/tratamento farmacológico , Prilocaína/uso terapêutico , Administração por Inalação , Administração Tópica , Adulto , Idoso , Idoso de 80 Anos ou mais , Anestésicos Combinados/uso terapêutico , Doença Crônica/terapia , Combinação de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
15.
Acta pediatr. esp ; 74(10): 253-259, nov. 2016. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-158371

RESUMO

Introducción: La realización de estudios de resonancia magnética (RM) en el paciente pediátrico frecuentemente precisa una sedación profunda. Pacientes y métodos: Estudio retrospectivo observacional sobre los procedimientos de RM que precisaron sedación, administrada por pediatras de la unidad de cuidados intensivos pediátrica de un hospital de segundo nivel. Se estudió el periodo comprendido entre noviembre de 2012 y octubre de 2015. Sólo se incluyeron estudios programados, no de urgencia. Resultados: La muestra válida fue de 286 estudios radiológicos; 273 (95,45%) precisaron sedación profunda, efectuada a 241 pacientes. La edad de los pacientes osciló entre 5 días y 16 años (39,82 ± 36,51 meses), la media de peso era de 14,41 ± 9,28 kg, y el 59,8% eran varones. La duración del estudio fue 23,43 ± 10,34 minutos. Del total de 241 pacientes, 82 (34%) tenían un déficit neurológico y 44 (18%) recibían algún medicamento antiepiléptico. El régimen anestésico más empleado fue la combinación de midazolam con propofol (236 casos de 273 [86,44%]). La prevalencia total de complicaciones fue del 4,75%, ninguna grave, y el estudio se pudo completar en el 100% de los casos. No se encontraron diferencias significativas en la dosificación del propofol en la subpoblación con déficit neurológico, aunque sí en la pauta de ketamina, que precisó una dosis más alta. La toma concomitante de medicación antiepiléptica en los pacientes con déficit neurológico requirió un aumento significativo de la dosis necesaria de propofol respecto a los pacientes con déficit neurológico sin medicación antiepiléptica. Conclusiones: La sedación profunda para la realización de estudios de RM puede efectuarse de forma segura por pediatras adecuadamente entrenados. La toma de medicación antiepiléptica puede variar la dosis necesaria de fármacos anestésicos en los pacientes con déficit neurológico (AU)


Introduction: Magnetic resonance imaging (MRI) studies frequently need to be obtained under deep sedation in pediatric patients. Patients and methods: An observational retrospective study was conducted to evaluate the sedation provided by pediatricians of the pediatric intensive care unit at a second level hospital for the realization of MRI studies. Urgent studies were excluded. Results: From November 2012 to October 2015, 286 studies of 241 patients met inclusion criteria. 273/286 (95.45%) examinations needed deep sedation. Results are shown in medians ± standard deviations. Age ranged from 5 days to 16 years (39.82 ± 36.51 months); weight was 14.41 ± 9.28 kg; 59.8% were male. The MRI took place during a median of 23.43 ± 10.34 minutes; 82 patients (34%) were developmentally disabled children and 44 (18%) took antiepileptic drugs. The most common anesthesic technique used was the combination of propofol plus midazolam (236/273 [86.44%]). Adverse events occurred in 4.75% of the cases, but none was serious. All MRI studies could be completed. Overall there were no significant differences in propofol dosage in relation to developmental disability, but a significant difference in ketamine dosage was found, with the developmental disabled needing more ketamine dosage. The patients with developmental disability who received antiepileptic drugs needed more propofol dose than the ones who did not take antiepileptic therapies. Conclusions: Appropriately trained sedation pediatricians can safely provide deep sedation for MRI studies. Antiepileptic drug intake can vary anaesthesic requirements in developmentally disabled children (AU)


Assuntos
Humanos , Masculino , Feminino , Criança , Pré-Escolar , Espectroscopia de Ressonância Magnética/métodos , Sedação Profunda/métodos , Anestésicos Combinados/uso terapêutico , Propofol/uso terapêutico , Ketamina/uso terapêutico , Anestésicos/efeitos adversos , Anticonvulsivantes/efeitos adversos , Estudo Observacional , Estudos Retrospectivos
16.
Medicine (Baltimore) ; 95(33): e4576, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27537587

RESUMO

Intraoperative dexmedetomidine (DEX) with or without loading dose both promote morphine-sparing effect in patient-controlled analgesia on postoperative acute pain. However, the contribution of the loading dose to this effect is largely unknown, especially in long-lasting surgeries. The present study was designed to investigate the role of a loading dose of DEX in this morphine-sparing effect in multiple-fracture patients following general anesthesia.Eighty-six patients scheduled multiple-fracture surgeries under general anesthesia were allocated into 3 groups which were maintained with propofol/remifentanil/Ringer solution (PRR), propofol/remifentanil/DEX with (PRDw), or without (PRDo) DEX loading dose before induction, respectively. Time to first morphine request and 24-hour morphine consumption was monitored. Pain intensity was evaluated with visual analog scale.During the first 24 hours following surgery, patients in the PRDw/o group showed increased time to first request of postoperative morphine and decreased total morphine consumption as compared with PRR patients. There was no significant difference with respect to these parameters between patients from the PRDw and PRDo groups. More patients from the PRDw groups experienced intraoperative bradycardia when compared to those from the PRR or PRDo group.This randomized controlled trial indicates that the morphine-sparing effect of intraoperative DEX was not affected by a loading dose in long-time surgeries.


Assuntos
Analgésicos não Narcóticos/uso terapêutico , Anestesia Geral/métodos , Anestésicos Combinados/uso terapêutico , Dexmedetomidina/uso terapêutico , Fixação Interna de Fraturas/métodos , Fraturas Múltiplas/cirurgia , Morfina/uso terapêutico , Dor Pós-Operatória/tratamento farmacológico , Adulto , Analgésicos não Narcóticos/administração & dosagem , Anestésicos Combinados/administração & dosagem , Dexmedetomidina/administração & dosagem , Feminino , Humanos , Período Intraoperatório , Masculino , Pessoa de Meia-Idade , Morfina/administração & dosagem , Medição da Dor , Período Pós-Operatório , Estudos Prospectivos
17.
Rev. Soc. Esp. Dolor ; 23(3): 159-163, mayo-jun. 2016. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-153267

RESUMO

La premisa básica de una combinación analgésica es que los dos fármacos actúen a través de diferentes mecanismos de acción; de esta manera, la combinación puede resultar una reducción de los efectos adversos relacionados con la dosis. Sin embargo, la utilidad de la administración conjunta de fármacos del mismo grupo farmacológico es un argumento controvertido pero resulta eficaz en algunas enfermedades, como la depresión y la epilepsia. La rápida necesidad de intensificar las dosis de opioides es un reto para los médicos y representa una fase crítica para los pacientes que tienen un mal control del dolor a pesar de recibir progresivamente crecientes dosis de opioides. La administración de pequeñas dosis de un segundo opioide en pacientes con una respuesta desfavorable durante la escalada con el opioide previo se ha encontrado eficaz en un informe preliminar donde se añadieron: morfina oral, fentanilo transdérmico y la metadona oral a fentanilo transdérmico, la morfina oral y morfina bucal, respectivamente. Así, aunque en la práctica clínica múltiples opioides se administran a menudo de forma simultánea por diferentes razones, hay pocos estudios que hayan evaluado este tema específico (AU)


The basic premise of an analgesic combination is that the two drugs act through different mechanisms of action; thus, the combination may be a reduction in adverse effects associated with the dose. However, the usefulness of the joint administration of drugs of the same pharmacological group is a controversial argument but is effective in some diseases, such as depression and epilepsy. The rapid need for increased doses of opioids is a challenge for physicians and represents a critical phase for patients who have a poor pain control despite receiving progressively increasing doses of opioids. The administration of small dose of a second opioid in patients with an unfavorable response during the escalation of the previous opioid has been found effective in a preliminary report which were added: oral morphine, transdermal fentanyl and oral methadone transdermal fentanyl oral morphine and oral morphine, respectively. Thus, although in clinical practice multiple opioids are often administered simultaneously for different reasons, few studies have evaluated this specific issue (AU)


Assuntos
Humanos , Masculino , Feminino , Anestésicos Combinados/administração & dosagem , Anestésicos Combinados/análise , Anestésicos Combinados/uso terapêutico , Analgésicos Opioides/administração & dosagem , Analgésicos Opioides/metabolismo , Analgésicos Opioides/uso terapêutico , Manejo da Dor/métodos , Anestésicos Combinados/metabolismo , Analgésicos Opioides/farmacologia , Manejo da Dor/instrumentação , Manejo da Dor
18.
Colorectal Dis ; 18(9): 903-9, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26850216

RESUMO

AIM: Colonoscopy performed as part of the NHS Bowel Cancer Screening Programme (BCSP) is of high standard as measured using global rating scale (GRS) criteria. Screening practitioners also provide a non-screening colonoscopy service. The current study compares colonoscopy quality indicators between screening and non-screening groups performed by a single practitioner using the GRS. METHOD: Patient details were obtained for all consecutive colonoscopies between 2007 and 2014 performed by a single screening practitioner. Data were collected retrospectively from electronic patient records; BCSP Exeter database and non-screening colonoscopies were compared. Data included patient demographics (age, gender), sedation, and the GRS data including caecal intubation, adenoma and neoplasia detection rates. RESULTS: In all, 1961 colonoscopy procedures (1067 screening and 894 non-screening) were identified; 57% were men. Mean (SD) age for all patients was 64 (± 10.4) years. Non-screening patients were younger [62 (± 14) vs 66 (± 4.8) years; P < 0.05] and were less likely to be men (51.5% vs 61.9%; P < 0.05) than their screening counterparts. Caecal intubation was more successful in screening patients [1027/1067 (96.3%)] than non-screening patients [805/894 (90%)]; P < 0.05. Adenoma detection rate was higher in the screening (46.8 ± 4.4) than non-screening (26.3 ± 11.8) group; P < 0.05. There were no differences in neoplasia detection. Polypectomy was more likely (55.5% vs 30.2%) and polyp retrieval more successful (97.5% vs 86.7%) in the screening group. CONCLUSION: Screening and non-screening colonoscopy differ in the GRS domains of completion and pathology detection. These differences need to be acknowledged when comparing screeners and non-screeners using GRS within units.


Assuntos
Adenoma/diagnóstico , Carcinoma/diagnóstico , Pólipos do Colo/diagnóstico , Colonoscopia/métodos , Neoplasias Colorretais/diagnóstico , Divertículo/diagnóstico , Doenças Inflamatórias Intestinais/diagnóstico , Indicadores de Qualidade em Assistência à Saúde , Adjuvantes Anestésicos/uso terapêutico , Idoso , Anestésicos Combinados/uso terapêutico , Brometo de Butilescopolamônio/uso terapêutico , Colite/diagnóstico , Colite Ulcerativa/diagnóstico , Doença de Crohn/diagnóstico , Diverticulite/diagnóstico , Detecção Precoce de Câncer , Feminino , Fentanila/uso terapêutico , Humanos , Masculino , Meperidina/uso terapêutico , Midazolam/uso terapêutico , Pessoa de Meia-Idade , Óxido Nitroso/uso terapêutico , Oxigênio/uso terapêutico , Estudos Retrospectivos , Medicina Estatal , Reino Unido
19.
Pediatr Emerg Care ; 32(7): 440-3, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25474094

RESUMO

BACKGROUND: Well-managed pain is associated with faster recovery, fewer complications, and decreased use of resources. In children, pain relief is also associated with higher patient and parent satisfaction. Studies have shown that there are deficiencies in pediatric pain management. LET gel (lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5%) is a topical anesthetic that is routinely used before laceration repair. OBJECTIVE: The aim of this study was to determine if educational initiatives as part of a quality improvement initiative lead to increased rates of early topical anesthetic usage in a large urban pediatric emergency department. METHODS: The initiative consisted of an educational session and a triage booth poster. We then reviewed the charts of patients with facial and scalp lacerations for the month before the initiative, the month after the initiative, and 1 year after the initiative. We assessed if LET gel usage and time to administration improved and were sustainable. RESULTS: We reviewed 138 charts. Before the initiative, only 57.4% received LET gel before facial laceration repair with a mean time to application of 58.3 minutes. One month after the initiative, there was an increase in LET gel application by 20.1% with a reduction in time to application by 35.9 minutes (P < 0.05). In addition, these improvements were significantly sustainable. One year after the interventions, 82.4% received LET before facial laceration repair, and the time to LET application was 27.8 minutes. CONCLUSIONS: Simple educational initiatives can improve the use of topical anesthetics. By using educational tools as part of a quality improvement initiative, we were able to significantly improve the rates of LET gel application for facial lacerations in children and decrease the time to administration.


Assuntos
Anestésicos Combinados/uso terapêutico , Anestésicos Locais/uso terapêutico , Serviço Hospitalar de Emergência , Epinefrina/uso terapêutico , Lacerações/tratamento farmacológico , Lidocaína/uso terapêutico , Manejo da Dor/métodos , Melhoria de Qualidade , Tetracaína/uso terapêutico , Administração Tópica , Criança , Combinação de Medicamentos , Feminino , Géis , Humanos , Masculino , Resultado do Tratamento , Triagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...